W. Gu

Immune enhancement to prevent infected pancreatic necrosis: A double-blind randomized controlled trial

Y. Liu, G. Doig, X. Pan, 2021, medRxiv.

The comprehensive analysis of efficacy and safety of CalliSpheres® drug-eluting beads transarterial chemoembolization in 367 liver cancer patients: a multiplecenter, cohort study.

Hongjie Hu, G. Shao, W.-B. Ji, 2019, Oncology research.

Efficacy and safety of drug-eluting beads transarterial chemoembolization by CalliSpheres® in 275 hepatocellular carcinoma patients: results from the Chinese CalliSpheres® Transarterial Chemoembolization In Liver Cancer (CTILC) study.

Hongjie Hu, G. Shao, W.-B. Ji, 2020, Oncology research.

Efficacy and safety of CalliSpheres® drug-eluting beads transarterial chemoembolization in patients with secondary liver cancer: a preliminary result from CTILC study

Hongjie Hu, W.-B. Ji, J. Ji, 2019, Translational cancer research.

Efficacy and safety of CalliSpheres® drug-eluting beads transarterial chemoembolization in patients with secondary liver cancer: a preliminary result from CTILC study

Hongjie Hu, G. Shao, W.-B. Ji, 2019, Translational cancer research.

Drug-eluting beads transarterial chemoembolization by CalliSpheres is effective and well tolerated in treating intrahepatic cholangiocarcinoma patients

Hongjie Hu, G. Shao, W.-B. Ji, 2020, Medicine.

Surgical treatment for early hepatocellular carcinoma: comparison of resection and liver transplantation

Z. Wang, S. Qiu, Jia Fan, 2010, Journal of Cancer Research and Clinical Oncology.

CalliSpheres® drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study

J. Fang, G. Shao, Tong Li, 2018, Clinical and Translational Oncology.